Cargando…

Correlation of Thyroid Transcription Factor-1 Expression with EGFR Mutations in Non-Small-Cell Lung Cancer: A Meta-Analysis

Objectives: This meta-analysis investigated the relationship between thyroid transcription factor-1 (TTF-1) expression and epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) to clarify whether TTF-1 can be a potential surrogate marker for EGFR mutation status in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyeong Su, Kim, Jung Han, Han, Boram, Choi, Dae Ro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410251/ https://www.ncbi.nlm.nih.gov/pubmed/30736438 http://dx.doi.org/10.3390/medicina55020041

Ejemplares similares

Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Kim, Jung Han, et al.
Publicado: (2018)

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
por: Lee, Taebum, et al.
Publicado: (2016)

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis
por: Kim, Hyeong Su, et al.
Publicado: (2019)

Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review
por: Kim, Hyeong Su, et al.
Publicado: (2018)

MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations
por: Park, Ji Young, et al.
Publicado: (2019)

Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2018)

Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer
por: Kim, Jung Soo, et al.
Publicado: (2017)

Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating EGFR Somatic Mutations
por: Choi, Kuicheon, et al.
Publicado: (2007)

Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review
por: Kim, Bum Jun, et al.
Publicado: (2017)

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017)

The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis
por: Kim, Bum Jun, et al.
Publicado: (2017)

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations
por: Ding, Xiaosheng, et al.
Publicado: (2023)

The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials
por: Kim, Bum Jun, et al.
Publicado: (2017)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
por: Bai, Hao, et al.
Publicado: (2017)

Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer
por: Cho, Arthur, et al.
Publicado: (2016)

Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer
por: Kim, Insu, et al.
Publicado: (2023)

A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients
por: Jang, Geundoo, et al.
Publicado: (2013)

The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
por: Jung, Joo Young, et al.
Publicado: (2014)

The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors
por: Lee, Hyunwoo, et al.
Publicado: (2022)

Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
por: Kim, Tae‐Ok, et al.
Publicado: (2018)

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
por: Lee, Boram, et al.
Publicado: (2016)

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
por: Kim, Hye Sook, et al.
Publicado: (2013)

Significance of thyroid transcription factor 1 and Napsin A for prompting the status of EGFR mutations in lung adenocarcinoma patients
por: Ren, Xiaolu, et al.
Publicado: (2022)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

EGFR ‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis
por: Phan, Thang Thanh, et al.
Publicado: (2021)

A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer
por: Cui, Ran, et al.
Publicado: (2022)

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
por: Zhang, Yue-Lun, et al.
Publicado: (2016)

Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
por: Wang, Huan, et al.
Publicado: (2014)

Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non–small cell lung carcinoma
por: Nakra, Tripti, et al.
Publicado: (2021)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
por: Liu, Yang, et al.
Publicado: (2017)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer
por: Lee, Hyunwoo, et al.
Publicado: (2021)

EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review
por: Chen, Chang-Hung, et al.
Publicado: (2022)

Erratum to: Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
por: Wang, Huan, et al.
Publicado: (2014)

Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series
por: Shin, Hong-Joon, et al.
Publicado: (2019)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Correlation of EGFR G873R mutation with prognosis of docetaxel in non-small cell lung cancer
por: Tian, Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_99erfj38v0nv9qctnpksnq0mmm